NASDAQ:MYGN - Myriad Genetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.33 -0.07 (-0.20 %)
(As of 05/21/2018 12:51 PM ET)
Previous Close$35.40
Today's Range$35.28 - $35.95
52-Week Range$19.75 - $41.57
Volume161,550 shs
Average Volume710,525 shs
Market Capitalization$2.47 billion
P/E Ratio33.65
Dividend YieldN/A
Beta0.51

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer. In addition, the company offers myPath Melanoma, a RNA expression test for diagnosing melanoma; myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency; and GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients. Further, it provides biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Debt-to-Equity Ratio0.07
Current Ratio3.52
Quick Ratio3.16

Price-To-Earnings

Trailing P/E Ratio33.65
Forward P/E Ratio29.44
P/E Growth3.81

Sales & Book Value

Annual Sales$771.40 million
Price / Sales3.20
Cash Flow$1.7683 per share
Price / Cash19.98
Book Value$11.42 per share
Price / Book3.09

Profitability

EPS (Most Recent Fiscal Year)$1.05
Net Income$21.80 million
Net Margins17.67%
Return on Equity9.52%
Return on Assets6.82%

Miscellaneous

Employees2,400
Outstanding Shares69,910,000

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics (NASDAQ:MYGN) posted its earnings results on Tuesday, May, 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.04. The business had revenue of $193.50 million for the quarter, compared to the consensus estimate of $188.22 million. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The company's revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 EPS. View Myriad Genetics' Earnings History.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $1.19-1.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.15. The company issued revenue guidance of $771-773 million, compared to the consensus revenue estimate of $770.43 million.

What price target have analysts set for MYGN?

11 Wall Street analysts have issued 1 year price objectives for Myriad Genetics' stock. Their predictions range from $16.00 to $45.00. On average, they expect Myriad Genetics' stock price to reach $30.9091 in the next year. View Analyst Ratings for Myriad Genetics.

What are Wall Street analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:
  • 1. According to Zacks Investment Research, "Despite weakness in Hereditary Cancer testing revenues, Myriad Genetics exited the third quarter of fiscal 2018 on a promising note. The company observed strong growth in GeneSight, Vectra DA and Prolaris testing revenues. Also, Hereditary Cancer volumes expansion was impressive. Furthermore, we are upbeat about the company seeing growth in new product volumes and success of its Elevate 2020 program. Moreover, the company's latest receipt of manufacturing and marketing approval for its BRACAnalysis Diagnostic System in Japan, buoys optimism. Further, the raised FY18 guidance instills confidence in investors. Accordingly, over the past three months, the company has outperformed its industry. However, the decline in Hereditary cancer testing revenues due to price reductions in long-term contracts, raises a concern. Additionally, currency fluctuations and stiff competition are major headwinds." (5/18/2018)
  • 2. Stephens analysts commented, "We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment." (1/3/2018)

Who are some of Myriad Genetics' key competitors?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:
  • Mr. Mark Christopher Capone, Pres, CEO & Director (Age 56)
  • Mr. R. Bryan Riggsbee, CFO & Treasurer (Age 47)
  • Dr. Jerry S. Lanchbury Ph.D., Chief Scientific Officer (Age 59)
  • Mr. Richard M. Marsh Esq., Exec. VP, Gen. Counsel & Sec. (Age 60)
  • Mr. Alexander Ford, Pres of Myriad Genetic Laboratories, Inc. (Age 51)

Has Myriad Genetics been receiving favorable news coverage?

Media headlines about MYGN stock have been trending very positive this week, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Myriad Genetics earned a news impact score of 0.51 on Accern's scale. They also assigned headlines about the company an impact score of 47.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.88%), Baillie Gifford & Co. (13.69%), Dimensional Fund Advisors LP (5.03%), Thrivent Financial for Lutherans (4.08%), Frontier Capital Management Co. LLC (2.88%) and Northern Trust Corp (2.51%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Millennium Management LLC, Caisse DE Depot ET Placement DU Quebec, Alambic Investment Management L.P., Baillie Gifford & Co., California Public Employees Retirement System, Pinnacle Associates Ltd. and Disciplined Growth Investors Inc. MN. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, Gary A King, Heinrich Dreismann, John T Henderson, Richard M Marsh and Walter Phd Gilbert. View Insider Buying and Selling for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was bought by a variety of institutional investors in the last quarter, including Sensato Investors LLC, Matarin Capital Management LLC, BlackRock Inc., Allianz Asset Management GmbH, UBS Group AG, JPMorgan Chase & Co., Northern Trust Corp and Federated Investors Inc. PA. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $35.35.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $2.47 billion and generates $771.40 million in revenue each year. The company earns $21.80 million in net income (profit) each year or $1.05 on an earnings per share basis. Myriad Genetics employs 2,400 workers across the globe.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  491 (Vote Underperform)
Total Votes:  787
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myriad Genetics (NASDAQ:MYGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Myriad Genetics in the last 12 months. Their average twelve-month price target is $30.9091, suggesting that the stock has a possible downside of 12.51%. The high price target for MYGN is $45.00 and the low price target for MYGN is $16.00. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.001.911.90
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.9091$30.4545$30.4545$26.5556
Price Target Upside: 12.51% downside2.89% upside9.71% downside14.75% downside

Myriad Genetics (NASDAQ:MYGN) Consensus Price Target History

Price Target History for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ:MYGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$33.00 ➝ $35.00MediumView Rating Details
5/8/2018BTIG ResearchSet Price TargetBuy$42.00MediumView Rating Details
2/7/2018Leerink SwannBoost Price TargetMarket Perform ➝ Market Perform$33.00 ➝ $35.00HighView Rating Details
1/29/2018Goldman SachsInitiated CoverageSell ➝ Sell$32.00HighView Rating Details
1/22/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$30.00 ➝ $35.00LowView Rating Details
1/3/2018StephensSet Price TargetBuy$45.00MediumView Rating Details
11/8/2017Deutsche BankBoost Price TargetHold$28.00 ➝ $30.00N/AView Rating Details
9/17/2017CowenReiterated RatingHold$25.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingHold$21.00 ➝ $23.00HighView Rating Details
7/14/2017Piper Jaffray CompaniesReiterated RatingHold$22.00LowView Rating Details
6/30/2017JPMorgan ChaseReiterated RatingUnderweight$16.00LowView Rating Details
2/8/2017Ladenburg ThalmannUpgradeSell ➝ NeutralN/AView Rating Details
10/10/2016Bank of AmericaReiterated RatingSellN/AView Rating Details
8/21/2016Wells FargoUpgradeMarket Perform ➝ OutperformN/AView Rating Details
8/10/2016UBSLower Price TargetSell$33.00 ➝ $18.00N/AView Rating Details
8/10/2016GabelliDowngradeBuy ➝ Hold$46.00 ➝ $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 ➝ $22.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Myriad Genetics (NASDAQ:MYGN) Earnings History and Estimates Chart

Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ:MYGN) Earnings Estimates

2018 EPS Consensus Estimate: $1.02
2019 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.19$0.21$0.20
Q2 20183$0.22$0.23$0.23
Q3 20183$0.26$0.28$0.27
Q4 20183$0.31$0.33$0.32
Q1 20193$0.30$0.32$0.31
Q2 20193$0.33$0.37$0.34
Q3 20193$0.31$0.36$0.34
Q4 20193$0.34$0.38$0.37

Myriad Genetics (NASDAQ MYGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q3$0.27$0.31$188.22 million$193.50 millionViewN/AView Earnings Details
2/6/2018Q2 2018$0.2360$0.31$188.72 million$194.00 millionViewListenView Earnings Details
11/7/2017Q1 2018$0.21$0.26$183.52 million$190.20 millionViewN/AView Earnings Details
8/8/2017Q4 17$0.26$0.30$193.71 million$200.50 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.2380$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
11/2/2010Q1 2011$0.23$0.24ViewN/AView Earnings Details
8/10/2010Q4 2010$0.33$0.39ViewN/AView Earnings Details
5/4/2010Q3 2010$0.38$0.33ViewN/AView Earnings Details
2/2/2010Q2 2010$0.34$0.36ViewN/AView Earnings Details
11/3/2009Q1 2010$0.32$0.31ViewN/AView Earnings Details
8/25/2009Q4 2009$0.23$0.37ViewN/AView Earnings Details
5/4/2009Q3 2009$0.23$0.25ViewN/AView Earnings Details
2/3/2009Q2 2009$0.17$0.22ViewN/AView Earnings Details
11/4/2008Q1 2009$0.07$0.15ViewN/AView Earnings Details
8/19/2008Q4 2008($0.12)$0.70ViewN/AView Earnings Details
5/6/2008Q3 2008($0.05)($0.05)ViewN/AView Earnings Details
2/5/2008Q2 2008($0.08)($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Myriad Genetics (NASDAQ:MYGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Myriad Genetics (NASDAQ MYGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics (NASDAQ MYGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Richard M MarshVPSell37,654$40.25$1,515,573.50157,648View SEC Filing  
1/18/2018Gary A KingVPSell3,120$38.12$118,934.40125,088View SEC Filing  
1/12/2018Richard M MarshVPSell13,759$36.25$498,763.75136,385View SEC Filing  
12/14/2017Walter Phd GilbertDirectorSell7,500$33.19$248,925.00View SEC Filing  
12/11/2017Heinrich DreismannDirectorSell6,000$33.50$201,000.0033,743View SEC Filing  
11/13/2017Alexander FordInsiderSell3,031$31.64$95,900.84View SEC Filing  
9/1/2017John T HendersonDirectorSell30,000$30.30$909,000.0052,524View SEC Filing  
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.0038,524View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.0049,493View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00146,026View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.0056,720View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.1940,122View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.0095,640View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.0095,640View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.0012,500View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.008,500View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.0010,000View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.0068,384View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.0080,573View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.3270,737View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.6070,737View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.3070,737View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.0067,543View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.4251,473View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.5851,473View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.0051,473View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.0051,473View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.0018,285View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.8018,285View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.2018,285View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00930View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.0047,609View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.0015,084View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.0026,084View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.0026,084View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.0017,165View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.5048,268View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.002,949View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.0047,609View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88324View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.9617,165View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.002,949View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.0017,165View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18324View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.0048,268View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.0047,609View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.0055,656View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.0047,177View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.0055,656View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Myriad Genetics (NASDAQ MYGN) News Headlines

Source:
DateHeadline
MYGN ALERT: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action - MYGNMYGN ALERT: Rosen Law Firm Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action - MYGN
www.prnewswire.com - May 19 at 11:48 AM
MYRIAD GENETICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGNMYRIAD GENETICS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Myriad Genetics, Inc. - MYGN
www.prnewswire.com - May 18 at 11:42 PM
Myriad Genetics (MYGN) Lowered to Hold at Zacks Investment ResearchMyriad Genetics (MYGN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:44 PM
Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)
www.fool.com - May 18 at 2:40 PM
Myriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and DirectorsMyriad Genetics, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors
finance.yahoo.com - May 18 at 10:35 AM
The Klein Law Firm Notifies Investors of a Class Action on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018The Klein Law Firm Notifies Investors of a Class Action on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 17 at 3:28 PM
Head to Head Review: Myriad Genetics (MYGN) vs. Vermillion (VRML)Head to Head Review: Myriad Genetics (MYGN) vs. Vermillion (VRML)
www.americanbankingnews.com - May 17 at 3:23 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline: June 19, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline: June 19, 2018
finance.yahoo.com - May 17 at 10:58 AM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGNEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGN
finance.yahoo.com - May 17 at 10:58 AM
Myriad Genetics (MYGN) Given Average Rating of "Hold" by AnalystsMyriad Genetics (MYGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 17 at 5:29 AM
MYGN EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018MYGN EQUITY ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 15 at 3:28 PM
Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual MeetingMyriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 15 at 11:05 AM
Kessler Topaz Meltzer & Check, LLP Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action LawsuitKessler Topaz Meltzer & Check, LLP Reminds Myriad Genetics, Inc. Investors of Important Deadline in Class Action Lawsuit
finance.yahoo.com - May 15 at 11:05 AM
Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual MeetingMyriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 15 at 11:05 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGNINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018 - MYGN
finance.yahoo.com - May 14 at 3:28 PM
Jefferies Group Comments on Myriad Genetics FY2018 Earnings (MYGN)Jefferies Group Comments on Myriad Genetics' FY2018 Earnings (MYGN)
www.americanbankingnews.com - May 14 at 3:32 AM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. (NASDAQ: MYGN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. (NASDAQ: MYGN) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
feeds.benzinga.com - May 13 at 11:09 PM
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGNEQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Myriad Genetics, Inc. – MYGN
finance.yahoo.com - May 12 at 11:13 AM
MYRIAD GENETICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in ...MYRIAD GENETICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in ...
www.businesswire.com - May 12 at 11:13 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGNSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Myriad Genetics, Inc. of Class Action Lawsuit and Upcoming Deadline – MYGN
feeds.benzinga.com - May 12 at 9:25 AM
Myriad Genetics (MYGN) Upgraded by BidaskClub to "Strong-Buy"Myriad Genetics (MYGN) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - May 11 at 7:50 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline - June 19, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Myriad Genetics, Inc. (MYGN) & Lead Plaintiff Deadline - June 19, 2018
finance.yahoo.com - May 11 at 3:37 PM
The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 11 at 3:37 PM
PAWAR LAW: Important June 19, 2018 Lead Plaintiff Deadline in Myriad Genetics, Inc. Class Action - MYGNPAWAR LAW: Important June 19, 2018 Lead Plaintiff Deadline in Myriad Genetics, Inc. Class Action - MYGN
finance.yahoo.com - May 11 at 10:34 AM
MYRIAD GENETICS, INC. INVESTOR UPDATE: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.MYRIAD GENETICS, INC. INVESTOR UPDATE: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Myriad Genetics, Inc.
finance.yahoo.com - May 11 at 10:34 AM
Is Myriad Genetics Inc (NASDAQ:MYGN) A Financially Strong Company?Is Myriad Genetics Inc (NASDAQ:MYGN) A Financially Strong Company?
finance.yahoo.com - May 11 at 10:34 AM
MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018MYGN EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Myriad Genetics, Inc. and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 10 at 3:28 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Myriad Genetics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 10 at 11:04 AM
Important Deadline Notice for Myriad Genetics, Inc. Shareholders - MYGNImportant Deadline Notice for Myriad Genetics, Inc. Shareholders - MYGN
finance.yahoo.com - May 10 at 11:04 AM
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the FirmINVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 10 at 11:04 AM
Myriad Genetics Sees Unusually High Options Volume (MYGN)Myriad Genetics Sees Unusually High Options Volume (MYGN)
www.americanbankingnews.com - May 10 at 8:02 AM
Myriad Genetics (MYGN) Forecasted to Post FY2018 Earnings of $1.21 Per ShareMyriad Genetics (MYGN) Forecasted to Post FY2018 Earnings of $1.21 Per Share
www.americanbankingnews.com - May 10 at 7:55 AM
BTIG Research Analysts Give Myriad Genetics (MYGN) a $42.00 Price TargetBTIG Research Analysts Give Myriad Genetics (MYGN) a $42.00 Price Target
www.americanbankingnews.com - May 9 at 5:12 PM
Myriad Genetics (MYGN) PT Raised to $35.00 at Morgan StanleyMyriad Genetics (MYGN) PT Raised to $35.00 at Morgan Stanley
www.americanbankingnews.com - May 9 at 4:43 PM
The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead ...The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead ...
globenewswire.com - May 9 at 3:31 PM
The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a ...The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a ...
www.businesswire.com - May 9 at 3:31 PM
MYRIAD GENETICS, INC.MYRIAD GENETICS, INC.
www.streetinsider.com - May 9 at 3:31 PM
BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16BRIEF-Myriad Genetics Reports Q3 GAAP Earnings Per Share $0.16
www.reuters.com - May 9 at 3:31 PM
Myriad Genetics, Inc. 2018 Q3 - Results - Earnings Call SlidesMyriad Genetics, Inc. 2018 Q3 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 3:31 PM
Myriad Genetics Spikes On Better-Than-Expected Q3 PrintMyriad Genetics Spikes On Better-Than-Expected Q3 Print
finance.yahoo.com - May 9 at 9:57 AM
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q3
www.zacks.com - May 9 at 9:57 AM
The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018The Klein Law Firm Announces a Class Action Commenced on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 9 at 9:57 AM
Edited Transcript of MYGN earnings conference call or presentation 8-May-18 11:30am GMTEdited Transcript of MYGN earnings conference call or presentation 8-May-18 11:30am GMT
finance.yahoo.com - May 9 at 9:57 AM
Deadline Alert for Myriad Genetics, Inc. Shareholders in Class Action Lawsuit - MYGNDeadline Alert for Myriad Genetics, Inc. Shareholders in Class Action Lawsuit - MYGN
finance.yahoo.com - May 9 at 9:57 AM
MYGN Makes Bullish Cross Above Critical Moving AverageMYGN Makes Bullish Cross Above Critical Moving Average
www.nasdaq.com - May 8 at 3:25 PM
Myriad Genetics (MYGN) Q3 2018 Results - Earnings Call TranscriptMyriad Genetics (MYGN) Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 3:25 PM
The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018The Klein Law Firm Announces a Class Action Filed on Behalf of Myriad Genetics, Inc. Shareholders and a Lead Plaintiff Deadline of June 19, 2018
finance.yahoo.com - May 8 at 3:25 PM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the FirmIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - May 8 at 3:25 PM
Myriad Genetics Inc. Q1 adjusted earnings Beat EstimatesMyriad Genetics Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 10:33 AM
Which Anti-Depressant is Right for You? Your DNA Can Shed Some LightWhich Anti-Depressant is Right for You? Your DNA Can Shed Some Light
finance.yahoo.com - May 8 at 10:33 AM

SEC Filings

Myriad Genetics (NASDAQ:MYGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myriad Genetics (NASDAQ:MYGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myriad Genetics (NASDAQ MYGN) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.